Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

The Lancet

Volumn 390, Issue 10101, 2017, Pages 1511-1520

  Alberer, Martin ^a   Gnad Vogt, Ulrike ^b   Hong, Henoch Sangjoon ^b   Mehr, Keyvan Tadjalli ^b   Backert, Linus ^c   Finak, Greg ^d   Gottardo, Raphael ^d   Bica, Mihai Alexandru ^b   Garofano, Aurelio ^b   Koch, Sven Dominik ^b   Fotin Mleczek, Mariola ^b   Hoerr, Ingmar ^b   Clemens, Ralf ^b   von Sonnenburg, Frank ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CureVac GmbH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NEUTRALIZING ANTIBODY; RABIES VACCINE; RNA VACCINE; VIRUS GLYCOPROTEIN; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RABIES; UNSPECIFIED SIDE EFFECT; VACCINATION; ADOLESCENT; ADVERSE DRUG REACTION; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; GERMANY; IMMUNOLOGY; VACCINE IMMUNOGENICITY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GERMANY; HUMANS; IMMUNOGENICITY, VACCINE; MALE; PROSPECTIVE STUDIES; RABIES; RABIES VACCINES; RNA, MESSENGER; YOUNG ADULT;

EID: 85025815073     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31665-3     Document Type: Article

References (27)

1. Greenwood, B, The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci, 369, 2014, 20130433.
2. Røttingen, JA, Gouglas, D, Feinberg, M, et al. New vaccines against epidemic infectious diseases. N Engl J Med 376 (2017), 610–613.
3. Ulmer, JB, Mason, PW, Geall, A, Mandl, CW, RNA-based vaccines. Vaccine 30 (2012), 4414–4448.
4. Maruggi, G, Chiarot, E, Giovani, C, et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35 (2017), 361–368.
5. Petsch, B, Schnee, M, Vogel, AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30 (2012), 1210–1216.
6. Hoerr, I, Obst, R, Rammensee, HG, Jung, G, In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30 (2000), 1–7.
7. Weide, B, Carralot, JP, Reese, A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31 (2008), 180–188.
8. Weide, B, Pascolo, S, Scheel, B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32 (2009), 498–507.
9. Sebastian, M, Papachristofilou, A, Weiss, C, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 14, 2014, 748.
10. Kübler, H, Scheel, B, Gnad-Vogt, U, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer, 3, 2015, 26.
11. Kranz, LM, Diken, M, Haas, H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
12. Carralot, JP, Probst, J, Hoerr, I, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 61 (2004), 2418–2424.
13. Schnee, M, Vogel, AB, Voss, D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Neg Trop Dis, 10, 2016, e0004746.
14. WHO. WHO Expert Consultation on Rabies First Report 2004. http://www.who.int/rabies/trs931_%2006_05.pdf (accessed June 27, 2017).
15. Human rabies: 2016 updates and call for data. Wkly Epidemiol Rec 92 (2017), 77–88.
16. Kis, EE, Winter, G, Myschik, J, Devices for intradermal vaccination. Vaccine 30 (2012), 523–538.
17. Roederer, M, Nozzi, JL, Nason, MC, SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79 (2011), 167–174.
18. Lin, L, Finak, G, Ushey, K, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnol 33 (2015), 610–616.
19. Marson, AG, Salinas, R, Bell's Palsy. West J Med 3 (2000), 573–576.
20. McAllister, L, Anderson, J, Werth, K, et al. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet 384 (2014), 674–681.
21. Simon, JK, Carter, M, Pasetti, MF, et al. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector. Vaccine 29 (2011), 9544–9550.
22. Jackson, LA, Austin, G, Chen, RT, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19 (2001), 4703–4709.
23. Geldenhuys, HD, Mearns, H, Foster, J, et al. A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guerin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe. Vaccine 33 (2015), 4719–4726.
24. Cui, Z, Baizer, L, Mumper, RJ, Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 102 (2003), 105–115.
25. Graham, BS, Enama, ME, Nason, MC, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One, 8, 2013, e59340.
26. Miller, JD, van der Most, RG, Akondy, RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28 (2008), 710–722.
27. Schmidt, T, Dirks, J, Enders, M, et al. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur J Immunol 42 (2012), 1755–1766.